Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

Changes in indinavir exposure over time: a case study in six HIV-1-infected children.

Fraaij PL, Bergshoeff AS, van Rossum AM, Hartwig NG, Burger DM, de Groot R.

J Antimicrob Chemother. 2003 Oct;52(4):727-30. Epub 2003 Aug 13.

2.

Pharmacokinetics of reduced-dose indinavir/ritonavir 400/100 mg twice daily in HIV-1-infected Thai patients.

Boyd M, Mootsikapun P, Burger D, Chuenyam T, Ubolyam S, Mahanontharit A, Sangkote J, Bunyaprawit P, Horsakulchai M, Lange J, Cooper D, Phanuphak P, Ruxrungtham K.

Antivir Ther. 2005;10(2):301-7.

PMID:
15865224
3.

Indinavir pharmacokinetics and parmacodynamics in children with human immunodeficiency virus infection.

Gatti G, Vigano' A, Sala N, Vella S, Bassetti M, Bassetti D, Principi N.

Antimicrob Agents Chemother. 2000 Mar;44(3):752-5.

4.

Pharmacokinetics of the protease inhibitor indinavir in human immunodeficiency virus type 1-infected children.

Burger DM, van Rossum AM, Hugen PW, Suur MH, Hartwig NG, Geelen SP, Scherpbier HJ, Hoetelmans RM, Vulto AG, de Groot R; Dutch Study Group for Children with HIV-1 Infection.

Antimicrob Agents Chemother. 2001 Mar;45(3):701-5.

5.

Plasma concentrations of the HIV-protease inhibitor lopinavir are suboptimal in children aged 2 years and below.

Verweel G, Burger DM, Sheehan NL, Bergshoeff AS, Warris A, van der Knaap LC, Driessen G, de Groot R, Hartwig NG.

Antivir Ther. 2007;12(4):453-8.

PMID:
17668553
6.

Pharmacokinetics of a once-daily regimen of lopinavir/ritonavir in HIV-1-infected children.

van der Lee M, Verweel G, de Groot R, Burger D.

Antivir Ther. 2006;11(4):439-45.

PMID:
16856617
7.

Pharmacokinetics of nelfinavir in children: influencing factors and dose implications.

Bergshoeff AS, Fraaij PL, van Rossum AM, Wolfs TF, Geelen SP, de Groot R, Burger DM.

Antivir Ther. 2003 Jun;8(3):215-22.

PMID:
12924538
8.

Switch from ritonavir to indinavir in combination therapy for HIV-1-infected children.

Pelton SI, Stanley K, Yogev R, Fletcher CV, McIntosh K, Wiznia A, Nachman S; Pediatric AIDS Clinical Trials Group 338 Study Team.

Clin Infect Dis. 2005 Apr 15;40(8):1181-7. Epub 2005 Mar 2.

9.

Interaction of sildenafil and indinavir when co-administered to HIV-positive patients.

Merry C, Barry MG, Ryan M, Tjia JF, Hennessy M, Eagling VA, Mulcahy F, Back DJ.

AIDS. 1999 Oct 22;13(15):F101-7.

PMID:
10546851
10.

Pharmacokinetics and pharmacodynamics of indinavir with or without low-dose ritonavir in HIV-infected Thai patients.

Burger D, Boyd M, Duncombe C, Felderhof M, Mahanontharit A, Ruxrungtham K, Ubolyam S, Stek M, Cooper D, Lange J, Phanupak P, Reiss P.

J Antimicrob Chemother. 2003 May;51(5):1231-8. Epub 2003 Mar 28.

11.

High variability of indinavir and nelfinavir pharmacokinetics in HIV-infected patients with a sustained virological response on highly active antiretroviral therapy.

Goujard C, Legrand M, Panhard X, Diquet B, Duval X, Peytavin G, Vincent I, Katlama C, Leport C, Bonnet B, Salmon-Céron D, Mentré F, Taburet AM; COPHAR1-ANRS 102 Study Group.

Clin Pharmacokinet. 2005;44(12):1267-78.

PMID:
16372824
12.

Lopinavir/ritonavir combined with twice-daily 400 mg indinavir: pharmacokinetics and pharmacodynamics in blood, CSF and semen.

Isaac A, Taylor S, Cane P, Smit E, Gibbons SE, White DJ, Drake SM, Khoo S, Back DJ.

J Antimicrob Chemother. 2004 Aug;54(2):498-502. Epub 2004 Jul 14.

13.

Intracellular and plasma pharmacokinetics of nelfinavir and M8 in HIV-infected patients: relationship with P-glycoprotein expression.

Ford J, Cornforth D, Hoggard PG, Cuthbertson Z, Meaden ER, Williams I, Johnson M, Daniels E, Hsyu P, Back DJ, Khoo SH.

Antivir Ther. 2004 Feb;9(1):77-84.

PMID:
15040539
14.

Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients.

Dieleman JP, Gyssens IC, van der Ende ME, de Marie S, Burger DM.

AIDS. 1999 Mar 11;13(4):473-8.

PMID:
10197375
15.

Indinavir trough concentration as a determinant of early nephrolithiasis in HIV-1-infected adults.

Collin F, Chêne G, Retout S, Peytavin G, Salmon D, Bouvet E, Raffi F, Garraffo R, Mentré F, Duval X; ANRS CO8 Aproco-Copilote Study Group.

Ther Drug Monit. 2007 Apr;29(2):164-70.

PMID:
17417069
16.

Persistent sterile leukocyturia is associated with impaired renal function in human immunodeficiency virus type 1-infected children treated with indinavir.

van Rossum AM, Dieleman JP, Fraaij PL, Cransberg K, Hartwig NG, Burger DM, Gyssens IC, de Groot R.

Pediatrics. 2002 Aug;110(2 Pt 1):e19.

PMID:
12165618
17.

Indinavir plasma concentration and adherence score are codeterminant of early virologic response in HIV-infected patients of the APROCO cohort.

Duval X, Mentré F, Lamotte C, Chêne G, Spire B, Dellamonica P, Panhard X, Salmon D, Raffi F, Peytavin G, Leport C; APROCO Study Group.

Ther Drug Monit. 2005 Feb;27(1):63-70. Erratum in: Ther Drug Monit. 2005 Aug;27(4):table of contents.

PMID:
15665749
18.

Low-doses of indinavir boosted with ritonavir in HIV-infected Thai patients: pharmacokinetics, efficacy and tolerability.

Cressey TR, Leenasirimakul P, Jourdain G, Tod M, Sukrakanchana PO, Kunkeaw S, Puttimit C, Lallemant M.

J Antimicrob Chemother. 2005 Jun;55(6):1041-4. Epub 2005 May 9.

19.

Effect of fluconazole on indinavir pharmacokinetics in human immunodeficiency virus-infected patients.

De Wit S, Debier M, De Smet M, McCrea J, Stone J, Carides A, Matthews C, Deutsch P, Clumeck N.

Antimicrob Agents Chemother. 1998 Feb;42(2):223-7.

20.

Maintenance of indinavir by dose adjustment in HIV-1-infected patients with indinavir-related toxicity.

Wasmuth JC, Lambertz I, Voigt E, Vogel M, Hoffmann C, Burger D, Rockstroh JK.

Eur J Clin Pharmacol. 2007 Oct;63(10):901-8. Epub 2007 Aug 10.

PMID:
17690876
Items per page

Supplemental Content

Write to the Help Desk